目的 探讨低分子肝素钙对急性脑梗死阿替普酶静脉溶栓后血管再闭塞患者的应用价值。方法 收集2010-2014年上海市同仁医院神经内科收治的经阿替普酶静脉溶栓后血管再闭塞的44例急性脑梗死患者资料,根据是否采用低分子肝素钙,分为抗凝组和对照组,抗凝组23例,对照组21例。评价两组治疗后1、14、90 d的疗效,包括神经功能缺损评分(NIHSS)及mRS评分,同时观察90 d内再脑出血发生率及病死率。结果 抗凝组和对照组14 d总有效率分别为78.3%、42.9%,差异有统计学意义(P＜0.05);90 d mRS评分分别为2.00±1.51、3.10±1.76,差异有统计学意义(P＜0.05)。抗凝组和对照组脑出血(症状性脑出血+非症状性脑出血)发生率分别为17.4％、14.3％,病死率分别为8.7%、9.5％,两组比较,差异均无统计学意义。结论 低分子肝素钙治疗阿替普酶溶栓后血管再闭塞,可改善患者神经功能,效果满意。
Abstract
Objective To study application value of the low molecular weight heparin calcium in re-occlusion patients in the process of thrombolysis with alteplase. Methods Forty-four patients with acute cerebral infarction admitted into this hospital in 2010-2014 were divided into observation group(n=23) and control groups(n=21).The former received low molecular weight heparin calcium combined with alteplase.The outcome scores were evaluated according to the National Institute of Heath Stroke Scale(NIHSS) before treatment and 1 d, 14 d after thrombolysis,the modified Rankin Scale (mRS) score after thrombolysis 90 d were observed,and the mortality, hemorrhagic transformation as the safety indicators were evaluated. Results There were significant differences in efficacy outcome rate (78.3%, 42.9%, respectively) between the two groups at 14 days (P<0.05). There were no significant differences between the two groups in the incidence of mortality and cerebral hemorrhage (symptomatic and non-symptomatic intracerebral hemorrhage) at 90 d. There were significant differences between the two groups at 90 d in mRS score (2.00±1.51, 3.10±1.76, respectively,P<0.05). Conclusions The treatment of the low molecular weight heparin calcium combined with alteplase in patients with aggravation of signs and symptoms in the process of thrombolysis can improve neurological function with satisfactory results.
关键词
急性缺血性卒中 /
阿替普酶 /
溶栓 /
再闭塞 /
低分子肝素钙
Key words
acute cerebral infarction /
alteplase /
thrombolysis /
re-occlusion /
low molecular weight heparin calcium
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 中华医学会神经病学分会脑血管病学组指南协作组. 2010 中国急性缺血性卒中诊治指南[J]. 中华神经科杂志,2010,43(2):146-154.
[2] Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J]. New England Journal of Medicine, 2008,359(13):1317-1329.
[3] Furie K L, Kasner S E, Adams R J, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J]. Stroke, 2011, 42(1):227-276.
[4] Fulgham J R, Ingall T J, Stead L G, et al. Management of acute ischemic stroke [J]. Mayo Clin Proc, 2004,79(11):1459-1469.
[5] Heo J H, Lee K Y, Kim S H, et al. Immediate re-occlusion following a successful thrombolysis in acute stroke: a pilot study [J]. Neurology, 2003,60(10):1684-1687.
[6] Grotta J C, Welch K M A, Fagan S C, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial [J]. Stroke, 2001,32(3):661-668.
[7] Adams H P, Del Zoppo G, Alberts M J, et al. Guidelines for the Early Management of Adults With Ischemic Stroke A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists[J]. Circulation, 2007,115(20):e478-e534.
[8] Toyoda K, Okada Y, Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study [J]. Cerebrov Dis, 2006,24(2-3):289-295.
[9] Alexandrov A V, Grotta J C. Arterial re-occlusion in stroke patients treated with intravenous tissue plasminogen activator[J]. Neurology, 2002,59(6):862-867.
[10] Straub S, Junghans U, Jovanovic V, et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion[J]. Stroke, 2004,35(3):705-709.
[11] Lyden P D. Stroke: Haemorrhage risk after thrombolysis—the SEDAN score [J]. Nature Reviews Neurology, 2012,8(5):246-247.
[12] Group I S T C. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke [J]. Lancet, 1997,349(9065):1569-1581.
[13] Chen Z M. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group [J]. Lancet, 1997,349(9066):1641-1649.
PDF(628 KB)
